10.38
前日終値:
$10.48
開ける:
$10.48
24時間の取引高:
3.94M
Relative Volume:
0.78
時価総額:
$7.73B
収益:
$125.68M
当期純損益:
$4.81B
株価収益率:
1.8372
EPS:
5.65
ネットキャッシュフロー:
$-781.21M
1週間 パフォーマンス:
-3.80%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
-9.58%
1年 パフォーマンス:
-1.52%
Roivant Sciences Ltd Stock (ROIV) Company Profile
名前
Roivant Sciences Ltd
セクター
電話
441-295-5950
住所
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
ROIV を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ROIV
Roivant Sciences Ltd
|
10.38 | 7.73B | 125.68M | 4.81B | -781.21M | 5.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-02-15 | 開始されました | Wolfe Research | Outperform |
2024-01-05 | 開始されました | Piper Sandler | Overweight |
2023-12-12 | 開始されました | Deutsche Bank | Buy |
2023-10-17 | 開始されました | Guggenheim | Buy |
2023-06-08 | 開始されました | BofA Securities | Neutral |
2022-10-27 | 開始されました | JP Morgan | Overweight |
2022-05-23 | 開始されました | SVB Leerink | Outperform |
2022-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
2021-12-15 | 開始されました | Goldman | Buy |
2021-11-08 | 開始されました | H.C. Wainwright | Buy |
2021-10-28 | 開始されました | Citigroup | Buy |
2021-10-26 | 開始されました | Cowen | Outperform |
2021-10-26 | 開始されました | Jefferies | Buy |
2021-10-26 | 開始されました | Truist | Buy |
すべてを表示
Roivant Sciences Ltd (ROIV) 最新ニュース
Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Yahoo Finance
Roivant Sciences president Eric Venker sells shares worth $8.19 million - Investing.com
Immunovant, Roivant slip after trial data for autoimmune disorder therapy - MSN
(ROIV) Trading Advice - Stock Traders Daily
Roivant Sciences finalizes consulting agreement with former officer - Investing.com India
Roivant Phase III Batoclimab Trial Is Positive, But No Filing Planned - News & Insights
Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint -March 19, 2025 at 08:24 am EDT - Marketscreener.com
Roivant Sciences Announces Positive Results for Batoclimab Studies - TipRanks
(ROIV) Trading Signals - Stock Traders Daily
Roivant at Leerink’s Conference: Strategic Insights and Developments By Investing.com - Investing.com Australia
Does Roivant (ROIV) Offer an Attractive Risk Reward Opportunity? - Insider Monkey
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Roivant Sciences Ltd. (ROIV): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by New York State Common Retirement Fund - Defense World
Trend Tracker for (ROIV) - Stock Traders Daily
Principal Financial Group Inc. Lowers Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Handelsbanken Fonder AB Trims Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Net worth of Vivek Ramaswamy: Roviant Sciences founder who is running for Ohio governor - The Times of India
Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant announces Resignation and Replacement of Arbutus Board - The Manila Times
Early Warning Report Issued Pursuant to National Instrument 62?103: Roivant announces Resignation and Replacement of Arbutus Board - Lelezard
Roivant Sciences president Eric Venker sells $1.07 million in shares - Investing.com India
Roivant Sciences appoints new Principal Accounting Officer By Investing.com - Investing.com South Africa
Roivant Sciences appoints new Principal Accounting Officer - Investing.com
Roivant Sciences Appoints New Chief Accounting Officer - TipRanks
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Sells 227,500 Shares of Stock - MarketBeat
Long Term Trading Analysis for (ROIV) - Stock Traders Daily
Roivant Sciences’ chief accounting officer sells $2.37 million in shares - Investing.com India
Roivant Sciences' chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Canada
Roivant Sciences’ chief accounting officer sells $2.37 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences' chief accounting officer sells $2.37 million in shares - Investing.com
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 218,041 Shares - MarketBeat
Roivant Sciences president Eric Venker sells over $4.56 million in stock - MSN
Roivant Sciences president Eric Venker sells over $4.56 million in stock By Investing.com - Investing.com South Africa
Roivant Sciences (NASDAQ:ROIV) Shares Gap Up After Earnings Beat - MarketBeat
178,853 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Elevate Capital Advisors LLC - MarketBeat
Roivant Sciences Ltd (ROIV) 財務データ
収益
当期純利益
現金流量
EPS
Roivant Sciences Ltd (ROIV) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Venker Eric | President & COO |
Mar 20 '25 |
Option Exercise |
3.85 |
400,000 |
1,540,000 |
1,274,979 |
Venker Eric | President & COO |
Mar 24 '25 |
Sale |
10.82 |
434,478 |
4,701,052 |
1,127,290 |
Venker Eric | President & COO |
Mar 20 '25 |
Sale |
11.06 |
315,522 |
3,489,673 |
959,457 |
大文字化:
|
ボリューム (24 時間):